Lectinlike oxidized low-density lipoprotein (LDL) receptor 1 (LOX-1), a cell surface receptor for oxidized LDL, has been implicated in vascular cell dysfunction related to plaque instability, which could be a potential target for an atherosclerosis imaging tracer. In this study, we designed and prepared 99m Tc-labeled anti-LOX-1 monoclonal IgG and investigated its usefulness as an atherosclerosis imaging agent. Methods: Anti-LOX-1 monoclonal IgG and control mouse IgG2a were labeled with 99m Tc after derivatization with 6-hydrazinonicotinic acid to yield 99m Tc-LOX-1-mAb and 99m TcIgG2a, respectively. Myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits (atherosclerosis model) and control rabbits were injected intravenously with these probes, and in vivo planar imaging was performed. At 24 h after the injection, the aortas were removed, and radioactivity was measured. Autoradiography and histologic studies were performed with serial aortic sections. Results: The level of 99m Tc-LOX-1-mAb accumulation was 2.0-fold higher than the level of 99m Tc-IgG2a accumulation in WHHLMI rabbit aortas, and the level of 99m Tc-LOX-1-mAb accumulation in WHHLMI rabbit aortas was 10.0-fold higher than the level of 99m Tc-LOX-1-mAb accumulation in control rabbit aortas. In vivo imaging clearly visualized the atherosclerotic aortas of WHHLMI rabbits. Autoradiography and histologic studies revealed that regional 99m Tc-IgG2a accumulation was independent of the histologic grade of the lesions; however, regional 99m Tc-LOX-1-mAb accumulation was significantly correlated with LOX-1 expression density and the vulnerability index. The highest level of 99m Tc-LOX-1-mAb accumulation, expressed as fradioactivity in region of interest (Bq/mm 2 )/[injected radioactivity (Bq)/animal body weight (g)]g · 10 2 , was found in atheromatous lesions (3.8 6 1.1 [mean 6 SD]), followed in decreasing order by fibroatheromatous lesions (2.0 6 1.0), collagen-rich lesions (1.6 6 0.8), and neointimal lesions (1.4 6 0.7). Conclusion: The level of 99m Tc-LOX-1-mAb accumulation in grade IV atheroma was higher than that in neointimal lesions or other, more stable lesions. Nuclear imaging of LOX-1 expression with 99m Tc-LOX-1-mAb may be a useful means for predicting atheroma at high risk for rupture.
Lectinlike oxidized low-density lipoprotein (LDL) receptor 1 (LOX-1), a cell surface receptor for oxidized LDL, has been implicated in vascular cell dysfunction related to plaque instability, which could be a potential target for an atherosclerosis imaging tracer. In this study, we designed and prepared 99m Tc-labeled anti-LOX-1 monoclonal IgG and investigated its usefulness as an atherosclerosis imaging agent. Methods: Anti-LOX-1 monoclonal IgG and control mouse IgG2a were labeled with 99m Tc after derivatization with 6-hydrazinonicotinic acid to yield 99m Tc-LOX-1-mAb and 99m TcIgG2a, respectively. Myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits (atherosclerosis model) and control rabbits were injected intravenously with these probes, and in vivo planar imaging was performed. At 24 h after the injection, the aortas were removed, and radioactivity was measured. Autoradiography and histologic studies were performed with serial aortic sections. Results: The level of 99m Tc-LOX-1-mAb accumulation was 2.0-fold higher than the level of 99m Tc-IgG2a accumulation in WHHLMI rabbit aortas, and the level of 99m Tc-LOX-1-mAb accumulation in WHHLMI rabbit aortas was 10.0-fold higher than the level of 99m Tc-LOX-1-mAb accumulation in control rabbit aortas. In vivo imaging clearly visualized the atherosclerotic aortas of WHHLMI rabbits. Autoradiography and histologic studies revealed that regional 99m Tc-IgG2a accumulation was independent of the histologic grade of the lesions; however, regional 99m Tc-LOX-1-mAb accumulation was significantly correlated with LOX-1 expression density and the vulnerability index. The highest level of 99m Tc-LOX-1-mAb accumulation, expressed as fradioactivity in region of interest (Bq/mm 2 )/[injected radioactivity (Bq)/animal body weight (g)]g · 10 2 , was found in atheromatous lesions (3.8 6 1.1 [mean 6 SD]), followed in decreasing order by fibroatheromatous lesions (2.0 6 1.0), collagen-rich lesions (1.6 6 0.8), and neointimal lesions (1.4 6 0.7). Conclusion: The level of 99m Tc- The spontaneous rupture of vulnerable atherosclerotic plaques and subsequent thrombus formation are currently recognized as the primary mechanisms of myocardial and cerebral infarctions (1) (2) (3) . Evaluation of the vulnerability of atherosclerotic lesions is therefore clinically important for stratifying risk and providing early treatment. At present, however, no noninvasive diagnostic tools for the evaluation of plaque vulnerability are available for routine clinical use. Accordingly, the development of such noninvasive tools is urgently required.
Oxidized low-density lipoprotein (LDL) has been implicated in the pathogenesis of atherosclerosis and atherosclerotic plaque rupture by promoting lipid accumulation and vascular dysfunction. Lectinlike oxidized LDL receptor 1 (LOX-1) mediates the biologic effects of oxidized LDL in this process (4) . Studies with cultured cells have suggested that LOX-1 may play several important roles in the destabilization of atherosclerotic plaques (5) (6) (7) (8) (9) . Furthermore, our recent animal study indicated that LOX-1 expression in atherosclerotic plaques was positively correlated with plaque instability in vivo (10) . Accordingly, the detection of LOX-1 expression may help assess the vulnerability of atherosclerotic plaques.
Nuclear medicine imaging enables the visualization of specific molecular processes in vivo and could be used for imaging of the in vivo biologic properties of atherosclerotic plaques beyond morphologic information (11, 12) . The development of radiopharmaceuticals for the evaluation of plaque vulnerability is a matter of great concern in the clinical diagnosis of atherosclerosis.
In this study, we designed and prepared 99m Tc-labeled anti-LOX-1 monoclonal IgG ( 99m Tc-LOX-1-mAb) for investigation as an atherosclerosis imaging agent and 99m Tclabeled control mouse IgG2a ( 99m Tc-IgG2a) for use as a control probe. Using an atherosclerosis model (myocardial infarction-prone Watanabe heritable hyperlipidemic [WHHLMI] rabbits) (13), we compared the accumulation of 99m Tc-LOX-1-mAb and 99m Tc-IgG2a in atherosclerotic lesions with histologic characteristics. Using these data, we evaluated the usefulness of 99m Tc-LOX-1-mAb as an atherosclerosis imaging agent.
MATERIALS AND METHODS
Design and Preparation of 99m Tc-LOX-1-mAb and 99m Tc-IgG2a
A monoclonal antibody for rabbit LOX-1 (mouse IgG2a subtype) was established by use of a standard hybridoma technique (10, 14) . 99m Tc-pertechnetate ( 99m TcO 4 2 ) from Daiichi Radioisotope Laboratory generators was eluted in saline solution on a daily basis.
Anti-LOX-1 monoclonal IgG (LOX-1-mAb) was radiolabeled with 99m Tc ( 99m Tc-LOX-1-mAb) after derivatization with 6-hydrazinonicotinic acid (HYNIC) (15) according to a previously reported procedure (16) with slight modifications. In brief, HYNIC-Nhydroxysuccinimide was reacted with LOX-1-mAb, and the mixture was purified by size exclusion chromatography (Sephadex G-50 Fine; Amersham Pharmacia Biotech). To the purified solution of HYNIC-LOX-1-mAb was added an equal volume of 99m Tc-(tricine) 2 , prepared by the method of Larsen et al. (17) , to obtain 99m Tc-LOX-1-mAb. After purification of 99m Tc-LOX-1-mAb by centrifugation of a size exclusion column with Sephadex G-50 Fine, the radiochemical purity of 99m Tc-LOX-1-mAb was determined by cellulose acetate electrophoresis (Separax; Joko Co. Ltd.) to be 95.4% 6 2.2% (mean 6 SD).
For the control study, negative control mouse IgG2a (Medical & Biologic Laboratories Co. Ltd.) was used for the preparation of 99m Tc-IgG2a [with HYNIC and (tricine) 2 ]. The radiochemical purity of 99m Tc-mouse IgG2a was 97.5% 6 0.9%.
Animal Preparation
All experimental procedures were approved by the Kyoto University Animal Care Committee. Three New Zealand White (NZW) rabbits (male, 3 mo old; Biotec, Inc.) were used to obtain peritoneal macrophages. For 99m Tc-LOX-1-mAb biodistribution studies, 8 WHHLMI rabbits (5 male and 3 female, 11-24 mo old, 3.2 6 0.5 kg; supplied by the Institute for Experimental Animals, Kobe University School of Medicine) were used. Six NZW rabbits (4 male and 2 female, 3.0 6 0.3 mo old, 2.6 6 0.5 kg; Biotec, Inc.) were used for the control study. For 99m Tc-IgG2a biodistribution studies, 3 WHHLMI rabbits (2 male and 1 female, 11-13 mo old, 2.8 6 0.2 kg) were used. The animals were fed standard chow (type CR-3; Clea Japan Inc.) at 120 g/d and were given water ad libitum.
Immunoreactivity of HYNIC-LOX-1-mAb
Rabbit peritoneal macrophages were obtained by the method of Ishii et al. (18) with minor modifications. The cells were suspended in medium A (Dulbecco's modified Eagle's medium containing 1 mM glutamine, penicillin at 100 U/mL, and streptomycin at 100 mg/mL [pH 7.4] as well as 0.2% lactalbumin hydrolysate) at a final concentration of 2.5 · 10 6 cells/mL. Aliquots of this cell suspension were placed in plastic petri dishes and then cultured in a humidified 5% CO 2 incubator at 37°C. After 2 h, each dish was washed twice with 10 mL of medium A to remove nonadherent cells. The monolayers were cultured for 18 h at 37°C in 20 mL of medium A, and the cells were washed twice with 10 mL of medium A and then used for experiments. More than 95% of the cells were viable, as determined by the trypan blue exclusion test, and almost all of the attached cells showed positive nonspecific esterase staining.
After the macrophages were stimulated for 6 h at 37°C in 5% CO 2 with tumor necrosis factor a at 10 ng/mL (Sigma-Aldrich, Inc.), the cells (10 6 ) were incubated with LOX-1-mAb (5 mg/mL, 100 mL), HYNIC-LOX-1-mAb (5 mg/mL, 100 mL), or control mouse IgG2a (5 mg/mL, 100 mL) for 30 min at 4°C. This step was followed by washing and incubation with Alexa Fluor 488 goat antimouse IgG (10 mg/mL, 100 mL; Molecular Probes, Inc.) for 30 min at 4°C. For flow cytometry analysis, cells were mixed with Iso-Flow solution (Beckman Coulter Inc.) and immediately analyzed with a FACScan instrument (Becton Dickinson Inc.). Data were analyzed with FACS software (BD CellQuest Pro; BD Biosciences Inc.). The immunoreactivity of HYNIC-LOX-1-mAb was evaluated on the basis of the median fluorescence intensity relative to that of control mouse IgG2a which, in turn, was compared with that of LOX-1-mAb. The measurements were obtained 3 times with rabbit peritoneal macrophages from 3 NZW rabbits, and the ratios were expressed as mean 6 SD.
Noninvasive Imaging
After 12 h of fasting, rabbits were initially anesthetized with ketamine (7 mg/kg, intramuscularly) and xylazine (1 mg/kg, intramuscularly). The anesthetic state was maintained with additional doses of ketamine and xylazine during the experimental period. The rabbits were placed on the scanner bed in the prone position to include the abdominal aorta in the field of view. 99m Tc-LOX-1-mAb (1,004 6 110 MBq, 300 mg) or 99m Tc-IgG2a (733 6 44 MBq, 300 mg) was injected into a marginal ear vein of the rabbits (3 WHHLMI rabbits and 3 control rabbits for the 99m Tc-LOX-1-mAb study and 3 WHHLMI rabbits for the 99m Tc-IgG2a study). At 10 min and 24 h after injection of the radiotracer, planar images were obtained for 10 min by use of a SPECT-2000H scanner (Hitachi Medical Co.) with a low-energy, high-resolution, parallel-hole collimator having a spatial resolution of 6.7 mm at full width at half maximum. Arterial blood samples were collected from an auricular artery at 24 h. All rabbits were also used in biodistribution studies.
Biodistribution Studies
After rabbits had fasted for 12 h, 99m Tc-LOX-1-mAb (122 6 65 MBq, 300 mg) or 99m Tc-IgG2a was injected into a marginal ear vein of the rabbits (8 WHHLMI rabbits and 6 control rabbits for the 99m Tc-LOX-1-mAb study and 3 WHHLMI rabbits for the 99m TcIgG study). At 24 h after the injection, all of the animals were sacrificed with an overdose of pentobarbital after blood sampling. The ascending aortic arch, the thoracic aorta, the abdominal aorta, the heart, and some femoral muscle were removed. The ascending aortic arch and thoracic and abdominal aortas were cut into 1-cm segments. Each segment was weighed and immediately fixed in a solution containing L-(1)-lysine hydrochloride (75 mM) and 4% paraformaldehyde in phosphate buffer (37.5 mM, pH 7.4) (19) . The radioactivity in each sample was measured with a well-type g-counter (ARC-2000; Aloka). The results were expressed as the differential uptake ratio (DUR), which was calculated as (tissue activity/tissue weight)/(injected radiotracer activity/animal body weight), with activities given in becquerels and weights given in grams. The aorta-to-blood ratio (A/B ratio) and the aorta-to-muscle ratio (A/M ratio) were calculated from the DUR for each tissue sample.
Autoradiography (ARG) Studies
A total of 8 segments, the second and fifth segments of the ascending aortic arch and the second, fifth, and eighth segments each of the thoracic and abdominal aortas, from each animal were used for ARG studies. These segments were frozen and cut into 20-mmthick slices with a cryomicrotome. The sections were thawed and mounted on silane-coated slides, which were then placed on a phosphorimaging plate (Fuji Imaging Plate BAS-UR; Fuji Photo Film) for 24 h together with a calibrated standard ( 99m TcO 4 2 solution) to obtain 99m Tc-LOX-1-mAb autoradiograms. The ARG images were analyzed by use of a computerized imaging analysis system (Bio Imaging Analyzer BAS3000 and Image Gauge Software; Fuji Photo Film). The radioactivity in each region of interest (ROI) was expressed as fradioactivity in ROI (Bq/mm 2 )/[injected radioactivity (Bq)/animal body weight (g)]g · 10 2 .
Histologic Analysis
The tissue sections used for ARG studies were also subjected to Azan-Mallory staining and hematoxylin-eosin (HE) staining. Therefore, ARG images were coincident with Azan-Mallory and HE images. Serial sections of the slices from the ARG studies were subjected to immunohistochemical staining (for LOX-1, macrophages, and smooth muscle cells). LOX-1 immunohistochemical staining was performed with LOX-1-mAb and an Envision1 kit (Dako) with hematoxylin counterstaining. In the same manner, immunohistochemical staining for macrophages and smooth muscle cells was performed with rabbit macrophage-specific monoclonal antibody RAM-11 (Dako) and human smooth muscle actin-specific monoclonal antibody 1A4 (Dako), respectively. Immunostaining with subclass-matched irrelevant IgG served as a negative control. Azan-Mallory staining and HE staining were performed by standard procedures. LOX-1 expression density was determined as a percentage of the positively stained region by use of a VHX digital microscope (Keyence Corp.).
To evaluate the correlation of 99m Tc-LOX-1-mAb accumulation with LOX-1 expression density (Fig. 1) , we divided each ARG image into 4 ROIs with vertical and horizontal lines as depicted in Figure 2B (dotted line) and then transferred the ROIs to the corresponding immunohistologic image (Fig. 2D, dotted line) .
Definition of Atherosclerotic Lesions
Atherosclerotic lesions in WHHLMI rabbit aortas were divided into 4 categories by use of a classification scheme based on the recommendations of the American Heart Association (AHA) (20, 21) and involving Azan-Mallory staining and HE staining as previously described (22) : neointimal lesions (types I-III), atheromatous lesions (type IV), fibroatheromatous lesions (types Va and Vb), and collagen-rich lesions (type Vc) (Figs. 3 and 4) .
Neointimal lesions (n 5 28 for 99m Tc-LOX-1-mAb study and n 5 7 for 99m Tc-IgG2a study) were defined as having adaptive thickening of the intima consisting of mainly smooth muscle cells and few ROIs were placed over the atherosclerotic lesions in the WHHLMI rabbit aortic sections with reference to the classification scheme based on the Azan-Mallory and HE staining images and then were transferred to the corresponding ARG images.
Vulnerability Index
An index of morphologic destabilization characteristics, the vulnerability index, was calculated for each lesion in the WHHLMI rabbits by the method of Shiomi et al. (26) The vulnerability index was defined as the ratio of the lipid component area (macrophages and extracellular lipid deposits) to the fibromuscular component area (smooth muscle cells and collagen fibers). Collagen fibers and extracellular lipid deposits (extracellular vacuoles and lacunae) were determined with Azan-Mallory staining. Macrophages and smooth muscle cells were determined with immunohistochemical staining (RAM-11 and 1A4).
Statistical Analysis
Data are presented as mean 6 SD. Statistical analysis was performed by use of the Mann-Whitney U test to compare aortic segments in WHHLMI and control rabbits (Table 1) . Correlation coefficients were assessed by use of Spearman rank analysis (Figs. 1 and 5). Comparisons among lesion types were performed by use of the Kruskal-Wallis test, and post hoc analysis was performed by use of the Scheffe test (Fig. 6) . A P value (2-tailed) of less than 0.05 was considered statistically significant.
RESULTS

Immunoreactivity of HYNIC-LOX-1-mAb
The median fluorescence intensity ratios for LOX-1-mAb and HYNIC-LOX-1-mAb relative to control mouse IgG2a were 1.63 6 0.08 and 1.52 6 0.11, respectively, indicating that the immunoreactivity of HYNIC-LOX-1-mAb was 93% that of LOX-1-mAb.
Noninvasive Imaging
The planar images showed primarily blood-pool radioactivity in the abdominal aorta at 10 min after the injection of 99m Tc-LOX-1-mAb or 99m Tc-IgG2a into WHHLMI and control rabbits (Figs. 7A-7C) . At 24 h, with decreased blood-pool radioactivity in the abdominal aorta, the atherosclerotic abdominal aorta with 99m Tc-LOX-1-mAb was more clearly visible than the control aorta with 99m Tc-LOX-1-mAb or the atherosclerotic aorta with 99m Tc-IgG2a (Figs. 7D-7F ).
Biodistribution Studies
The distributions of 99m Tc-LOX-1-mAb and 99m Tc-IgG2a in the aortic segments of WHHLMI and control rabbits are summarized in Table 1 . The level of 99m Tc-LOX-1-mAb accumulation in each aortic segment in WHHLMI rabbits was 7.9-to 12.1-fold higher than that in control rabbits, and the differences were significant. A significant difference in 99m Tc-LOX-1-mAb accumulation was not observed between young WHHLMI rabbits (11-13 mo) and old WHHLMI rabbits (20-24 mo) (DURs of 3.3 6 1.4 and 2.8 6 2.1, respectively). Blood-pool radioactivity levels (DURs) at 24 h were 4.5 6 0.5 and 3.5 6 0.4 in WHHLMI and control rabbits, respectively. A/B and A/M ratios were significantly higher in WHHLMI rabbits than in control rabbits. Relatively high levels of 99m Tc-LOX-1-mAb accumulation were found in the liver, spleen, and kidneys in both groups of rabbits (data not shown). No marked difference in the distribution of 99m Tc-LOX-1-mAb in nontarget organs was observed between WHHLMI and control rabbits.
The level of 99m Tc-LOX-1-mAb accumulation in WHHLMI rabbit aortas was 1.8-to 2.5-fold higher than the level of 99m Tc-IgG2a accumulation, and the differences were significant. In the ARG studies, heterogeneous 99m Tc-LOX-1-mAb accumulation was observed in the intima of the WHHLMI rabbit aortas, whereas there was little accumulation in the aortas of control rabbits ( Figs. 2A and 2B ). LOX-1 expression was detected in intimal lesions in WHHLMI rabbit aortas, and the levels of expression differed among the regions (Fig.  2D) . As shown in Figures 2B and 2D , higher levels of accumulation of 99m Tc-LOX-1-mAb were observed in regions with high levels of LOX-1 expression, whereas lower levels of accumulation were seen in regions with low levels of LOX-1 expression. Consequently, regional 99m Tc-LOX-1-mAb accumulation in WHHLMI rabbit aortic sections was significantly correlated with LOX-1 expression density (r 5 0.64, P , 0.0001) (Fig. 1) . No obvious LOX-1 expression was observed in the aortas of control rabbits (Fig. 2C) .
Correlation of Accumulation of 99m Tc-LOX-1-mAb and 99m Tc-IgG2a with Histologic Characteristics 99m Tc-LOX-1-mAb accumulation was dependent on the histologic grade of lesions (Figs. 4C and 6A) , and the highest (and significant; P , 0.0001) level was seen in atheromatous lesions (type IV), followed in decreasing order by fibroatheromatous, collagen-rich, and neointimal lesions. Figures 6B  and 6C show the macrophage density and vulnerability index quantified for each lesion in the 99m Tc-LOX-1-mAb study. The macrophage density and vulnerability index were also the highest in atheromatous lesions, followed in decreasing order by fibroatheromatous, neointimal, and collagen-rich lesions. Consequently, the highest values for 99m Tc-LOX-1-mAb accumulation, macrophage density, and the vulnerability index were observed in atheromatous lesions. In contrast, lower values for 99m Tc-LOX-1-mAb accumulation, macrophage density, and the vulnerability index were seen in collagen-rich and neointimal lesions. Figure 5A shows the regression analysis for 99m Tc-LOX-1-mAb accumulation and the vulnerability index. The regression analysis demonstrated a directly proportional relationship between 99m Tc-LOX-1-mAb accumulation and the vulnerability index (r 5 0.67, P , 0.0001).
In contrast, control tracer ( 99m Tc-IgG2a) accumulation was independent of the histologic grade of lesions, and the differences among the lesions were not significant (Figs. 4F   FIGURE 4 . Lesion classification scheme in representative photomicrographs and autoradiograms of cross sections of WHHLMI rabbit aortas in 99m Tc-LOX-1-mAb study (A-C) and 99m Tc-IgG2a study (D-F). Atherosclerotic lesions were assigned with AHA classification scheme from Azan-Mallory staining (A and D) and HE staining (B and E) (Fig. 3) . Same classification was applied to autoradiograms (ARG) (C and F). ROIs were placed over atherosclerotic lesions in WHHLMI rabbit aortic sections by reference to images with classification scheme from Azan-Mallory staining. a 5 atheromatous lesions; c 5 collagen-rich lesions; f 5 fibroatheromatous lesions. Bar 5 1 mm. and 6C). The 99m Tc-IgG2a distribution based on the lesion classification was different from that of 99m Tc-LOX-1-mAb, although the distributions of macrophage density and the vulnerability index in the 99m Tc-IgG2a study were similar to those in the 99m Tc-LOX-1-mAb study (data not shown). Furthermore, no correlation between 99m Tc-IgG2a accumulation and the vulnerability index was shown (r 5 0.002, P , 0.0001) (Fig. 5B) .
DISCUSSION
There is an urgent need to develop a means to discriminate vulnerable atherosclerotic lesions (atheromatous lesions) from potentially stable lesions in clinical practice, because the disruption of vulnerable plaques causes myocardial and cerebral infarctions. In the present study, we designed and prepared a new imaging agent, 99m Tc-LOX-1-mAb. Our results clearly indicated the potential of 99m Tc-LOX-1-mAb for targeting LOX-1 and evaluating the vulnerability of atherosclerotic lesions.
The immunoreactivity of an agent is an essential factor in in vivo imaging with immunodetection. Flow cytometry analyses indicated that the modification of LOX-1-mAb with the chelating moiety (HYNIC) did not significantly affect the immunoreactivity of the original LOX-1-mAb, although the mean fluorescence intensity was low. Furthermore, ARG and immunohistochemical studies showed that 99m Tc-LOX-1-mAb accumulation in atherosclerotic lesions was well correlated with LOX-1 expression density (Fig.  1) . These results suggested the potential of 99m Tc-LOX-1-mAb to specifically recognize LOX-1 in vivo.
The highest level of 99m Tc-LOX-1-mAb accumulation was seen in atheromatous lesions (Fig. 6A) and was significantly correlated with the vulnerability index (Fig. 5A) , indicating the ability of this agent to distinguish apparently vulnerable atheromatous lesions from more stable, chronic plaques. This result is consistent with the in vivo relationship between LOX-1 expression and lesion vulnerability (10) . In contrast, the relationship between 99m Tc-LOX-1-mAb accu- Tc-LOX-1-mAb study. Accumulation in each aortic segment was significantly higher in WHHLMI rabbits than in control rabbits. Ascending arch of aorta and thoracic aorta showed higher radioactivity than abdominal aorta in WHHLMI rabbits. mulation (LOX-1 signal) and macrophage density was not high (r 5 0.49, P , 0.001) (data not shown), compared with the relationship with the vulnerability index (Fig. 5A) . It has been reported that LOX-1 is intensely expressed in endothelial cells and macrophages (foam cells) in unstable atherosclerotic plaques (10, 27) . In the present study, LOX-1 expression was mainly observed in macrophages; however, LOX-1 was also expressed in endothelial cells and smooth muscle cells. LOX-1 plays multiphasic roles in the formation of vulnerable atherosclerotic plaques (5-9). Accordingly, although 99m Tc-LOX-1-mAb accumulation is not highly correlated with macrophage density, 99m Tc-LOX-1-mAb should provide clinically useful information about atherogenesis on the basis of the LOX-1 expression level.
In the present study, we applied a nuclear imaging technique for atherosclerosis imaging. Nuclear imaging is used with the aim of visualizing the biologic properties of atherosclerotic plaques (e.g., cellular composition, inflammatory cell activity, receptor expression, or apoptotic events) (11, 12) . Accordingly, nuclear imaging approaches could provide new diagnostic imaging capabilities for detecting vulnerable plaques on the basis of a specific biologic aspect of atherosclerosis progression. Tsimikas et al. reported the use of a 99m Tc-oxidized LDL-specific antibody for atherosclerosis imaging (28, 29) ; this agent allowed the detection of atherosclerosis progression and regression. However, oxidized LDL would need to be injected after the use of this agent to reduce a high level of accumulation of the antibody in the blood and liver. Furthermore, LOX-1 may be a more suitable target than oxidized LDL because it is a specific factor in atherosclerosis progression and is expressed during the early period of atherosclerosis. In contrast, nonspecific uptake into atherosclerosis lesions and high permeability of lesions are important concerns (30, 31) . Therefore, we performed a 99m Tc-IgG2a (control probe) study, which showed the specific uptake of 99m Tc-LOX-1-mAb in atherosclerotic plaques.
As representative nuclear imaging probes, 18 F-FDG for imaging metabolic activity in macrophages (19, 32) and 99m Tc-annexin A5 for imaging apoptosis (33, 34) were recently used for atherosclerotic plaque imaging. Consequently, it was especially important and intriguing to characterize 99m Tc-LOX-1-mAb in the same animal model (WHHLMI rabbits), focusing on the advantages of 99m Tc-LOX-1-mAb. First, the levels of 99m Tc-LOX-1-mAb accumulation were 2.4-and 3.2-fold higher than the levels of 18 F-FDG accumulation (DURs, 1.47 6 0.90 and 0.72 6 0.37) in the thoracic and abdominal aortic segments in WHHLMI rabbits, respectively (19) . Additionally, the level of 99m Tc-LOX-1-mAb accumulation was 5.2-fold higher than the level of 99m Tc-annexin A5 accumulation (DUR, 0.64 6 0.18 [total aorta]) in aortic segments in WHHLMI rabbits (33) . These results indicated the potential of 99m Tc-LOX-1-mAb for in vivo imaging, as the accumulation level is an essential factor for this purpose.
Second, 99m Tc-LOX-1-mAb accumulated predominantly in atheromatous lesions. The accumulation ratios of 99m Tc-LOX-1-mAb for atheromatous lesions to other lesions (atheromatous/neointimal, atheromatous/fibroatheromatous, and atheromatous/collagen-rich lesion ratios) were higher than those of 99m Tc-annexin A5 (2.7 vs. 1.3, 1.9 vs. 1.3, and 2.4 vs. 1.8, respectively), indicating that 99m Tc-LOX-1-mAb accumulated more selectively in atheromatous lesions. These results suggested the ability of 99m Tc-LOX-1-mAb to selectively detect vulnerable plaques among heterogeneous atherosclerotic lesions.
In noninvasive imaging studies with 99m Tc-LOX-1-mAb, the atherosclerotic abdominal aorta was imaged more clearly in WHHLMI rabbits than in control rabbits, with decreased blood-pool radioactivity in the abdominal aorta (Fig. 7) . This result was confirmed in biodistribution studies (Table 1) . However, the difference between control and WHHLMI rabbits seemed to be underwhelming when determined from ARG images, for various reasons. First, the spatial resolution of the SPECT images (6.7 mm at full width at half maximum) was lower than that of the ARG images (50 mm). Second, the A/B ratio in WHHLMI rabbits was 0.69 6 0.33 at 24 h, indicating that the radioactivity detected by noninvasive imaging was attributable to both aorta and blood radioactivity, although this A/B ratio was comparable to that of 99m Tcannexin A5 (1.0 6 0.2 at 3 h after injection). Johnson et al. reported the possibility of in vivo imaging of porcine coronary lesions with 99m Tc-annexin A5 (35) . However, further studies on the acceleration of clearance of radioactivity from the blood pool are necessary. It has been reported that radiopharmaceuticals derived from low-molecular-weight polypeptides or compounds, small recombinant antibody fragments (Fab and scFv), engineered variants (diabodies, triabodies, minibodies, and single-domain antibodies), and pretargeting antibody methods show rapid clearance of radioactivity from the circulation (36) (37) (38) . The technical progression of SPECT devices could also eliminate the highbackground problem.
CONCLUSION
We designed and prepared 99m Tc-LOX-1-mAb for the imaging of LOX-1 and characterized the accumulation of 99m Tc-LOX-1-mAb in atherosclerotic lesions in a rabbit model of spontaneous atherosclerosis. We demonstrated that 99m Tc-LOX-1-mAb could evaluate lesion vulnerability more sensitively than other imaging probes. It could be applied in the clinical setting because of the similarity of the histologic characteristics of atherosclerotic plaques in humans and WHHLMI rabbits. 99m Tc-LOX-1-mAb could be useful as a potential imaging probe for predicting lesions prone to spontaneous rupture and monitoring the effects of timely treatment in patients with advanced atherosclerosis.
